FI75094C - Förfarande för framställning av Propionibacterium granulosum, Propioni bacterium avidum och/eller Propionibacterium acnes cellväggs- eller he lcellsprodukter. - Google Patents
Förfarande för framställning av Propionibacterium granulosum, Propioni bacterium avidum och/eller Propionibacterium acnes cellväggs- eller he lcellsprodukter. Download PDFInfo
- Publication number
- FI75094C FI75094C FI810783A FI810783A FI75094C FI 75094 C FI75094 C FI 75094C FI 810783 A FI810783 A FI 810783A FI 810783 A FI810783 A FI 810783A FI 75094 C FI75094 C FI 75094C
- Authority
- FI
- Finland
- Prior art keywords
- propionibacterium
- granulosum
- cell
- mice
- avidum
- Prior art date
Links
- 241001464975 Cutibacterium granulosum Species 0.000 title claims description 34
- 238000002360 preparation method Methods 0.000 title claims description 26
- 210000004027 cell Anatomy 0.000 title claims description 23
- 238000000034 method Methods 0.000 title claims description 21
- 210000002421 cell wall Anatomy 0.000 title claims description 20
- 241001464974 Cutibacterium avidum Species 0.000 title claims description 17
- 241000186427 Cutibacterium acnes Species 0.000 title claims description 13
- 229940055009 propionibacterium avidum Drugs 0.000 title claims description 7
- 229940055019 propionibacterium acne Drugs 0.000 title claims description 4
- 241000894006 Bacteria Species 0.000 claims description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 239000000725 suspension Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 12
- 238000002512 chemotherapy Methods 0.000 claims description 11
- 239000011521 glass Substances 0.000 claims description 10
- 239000008363 phosphate buffer Substances 0.000 claims description 10
- 239000012153 distilled water Substances 0.000 claims description 9
- 239000011324 bead Substances 0.000 claims description 8
- 102000004142 Trypsin Human genes 0.000 claims description 6
- 108090000631 Trypsin Proteins 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 6
- 238000011534 incubation Methods 0.000 claims description 6
- 239000013049 sediment Substances 0.000 claims description 6
- 239000012588 trypsin Substances 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 5
- 239000008272 agar Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 239000002002 slurry Substances 0.000 claims description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 239000007836 KH2PO4 Substances 0.000 claims description 3
- 230000002358 autolytic effect Effects 0.000 claims description 3
- 210000000805 cytoplasm Anatomy 0.000 claims description 3
- 238000009630 liquid culture Methods 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 3
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 241000186429 Propionibacterium Species 0.000 claims description 2
- 238000009835 boiling Methods 0.000 claims description 2
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- 108010079058 casein hydrolysate Proteins 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 2
- 235000011009 potassium phosphates Nutrition 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- 239000001888 Peptone Substances 0.000 claims 1
- 108010080698 Peptones Proteins 0.000 claims 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 claims 1
- 235000019319 peptone Nutrition 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 62
- 241000699670 Mus sp. Species 0.000 description 47
- 235000019260 propionic acid Nutrition 0.000 description 31
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 31
- 241001465754 Metazoa Species 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 208000006268 Sarcoma 180 Diseases 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 230000001665 lethal effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 231100000518 lethal Toxicity 0.000 description 6
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 241001529936 Murinae Species 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000003393 splenic effect Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003978 infusion fluid Substances 0.000 description 3
- 208000037841 lung tumor Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 208000020154 Acnes Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 229940072358 xylocaine Drugs 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 102000016726 Coat Protein Complex I Human genes 0.000 description 1
- 108010092897 Coat Protein Complex I Proteins 0.000 description 1
- 241000689227 Cora <basidiomycete fungus> Species 0.000 description 1
- 244000304337 Cuminum cyminum Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 240000006890 Erythroxylum coca Species 0.000 description 1
- 244000187656 Eucalyptus cornuta Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000008957 cocaer Nutrition 0.000 description 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001373 regressive effect Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000000904 thermoluminescence Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (11)
1. Förfarande för framställning av ettcellvägg- eller hel-cellväggpreparat av Propionbacterium granulosum-, Propionbac-terium avidum- och/eller Propionbacterium acnesceller för an-vändning i radio- eller kemoterapin av tumörer, kanne-tecknat av att en vätskeodling av ifrägavarande pro-pionbakterie behandlas enligt Gas-Pak-metoden under anaero-biska betingelser, efter inkubering avskiljes cellerna genom kallslungning och sedimentet tvättas med destillerat vatten och eventuellt därefter krossas med glaspärlor i en cellkvarn, när den mikroskopiska kontrollen utvisar, att hela celler ej längre förekommer, glaspärlorna separeras frän homogenisatet med tillhjälp av ett glassinter under användning av en fosfat-buffert med pH-värdet 7,2, den cellväggar och cvtoplasma inne-hällande mjölkartade suspensionen centrifugeras och sedimentet upptas i fosfatbuffert med pH-värdet 7,2, autolytiska enzymer inaktiveras genom kokning, den tillvaratagna proteinhaltiga cellväggen renas genom inkubering med trypsinsuspension och toluen, de genom trypsinuppslutning renade cellväggarna separeras genom centrifugering, tvättas med destillerat vatten och frystorkas.
2. Förfarande enligt patentkrav 1, kännetecknat av att Gas-Pak-metoden utföres vid en temperatur av 37°C.
3. Förfarande enligt patentkrav 1, kännetecknat av att inkuberingen utföres under en tid av 72 timmar och vid en temperatur av 37°C.
4. Förfarande enligt patentkrav 1, kännetecknat av att cellernas krossning i cellkvarnen utföres genom att an-vända den dubbla volymen glaspärlor under 1-2 timmar.
5. Förfarande enligt patentkrav 3, kännetecknat av att glaspärlor med diametern 0,17 - 0,18 mm användes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI810783A FI75094C (sv) | 1981-03-13 | 1981-03-13 | Förfarande för framställning av Propionibacterium granulosum, Propioni bacterium avidum och/eller Propionibacterium acnes cellväggs- eller he lcellsprodukter. |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI810783 | 1981-03-13 | ||
| FI810783A FI75094C (sv) | 1981-03-13 | 1981-03-13 | Förfarande för framställning av Propionibacterium granulosum, Propioni bacterium avidum och/eller Propionibacterium acnes cellväggs- eller he lcellsprodukter. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI810783L FI810783L (fi) | 1982-09-14 |
| FI75094B FI75094B (fi) | 1988-01-29 |
| FI75094C true FI75094C (sv) | 1988-05-09 |
Family
ID=8514222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI810783A FI75094C (sv) | 1981-03-13 | 1981-03-13 | Förfarande för framställning av Propionibacterium granulosum, Propioni bacterium avidum och/eller Propionibacterium acnes cellväggs- eller he lcellsprodukter. |
Country Status (1)
| Country | Link |
|---|---|
| FI (1) | FI75094C (sv) |
-
1981
- 1981-03-13 FI FI810783A patent/FI75094C/sv not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FI75094B (fi) | 1988-01-29 |
| FI810783L (fi) | 1982-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2687227B1 (en) | Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response | |
| US4877611A (en) | Vaccine containing tumor antigens and adjuvants | |
| US3192116A (en) | Anti-tumor clostridium composition | |
| Milas et al. | Immunoprophylaxis and immunotherapy for a murine fibrosarcoma with C. granulosum and C. parvum | |
| SUZUKI et al. | Inhibition of Expeirmental Pulmonary Metastasis of Lewis Lung Carcinoma by Orally Administered β-Glucan in Mice | |
| US5759554A (en) | Immunostimulatory bacterial cell wall traction | |
| CH664897A5 (de) | Gereinigtes, entgiftetes endotoxin enthaltende pharmazeutische zusammensetzung. | |
| US3928565A (en) | Pharmaceutical preparation of pseudomonas aeruginosa bacterial component possessing anti-tumor and anti-infection properties | |
| CN114317377A (zh) | 一种修饰细菌及其制备方法和应用 | |
| US4647456A (en) | Methods of increasing tolerance to radiotherapy and chemotherapy using propioni bacteria | |
| FI75094C (sv) | Förfarande för framställning av Propionibacterium granulosum, Propioni bacterium avidum och/eller Propionibacterium acnes cellväggs- eller he lcellsprodukter. | |
| CN110041441B (zh) | 一种红花多糖、其制备方法及在抗肿瘤药物中的应用 | |
| UA79952C2 (en) | MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT | |
| Eisenstein et al. | Immunotherapy of a plasmacytoma with attenuated Salmonella | |
| CN110448681A (zh) | 一种用于恶性肿瘤免疫治疗的联合药物 | |
| Pierangeli et al. | Treatment of murine macrophages with murine interferon-gamma and tumour necrosis factor-alpha enhances uptake and intracellular killing of Pseudomonas aeruginosa | |
| SU1304736A3 (ru) | Способ получени противоопухолевого средства | |
| KR850000143B1 (ko) | 세포벽표본의 제조방법 | |
| Pulverer et al. | Combined immunomodulation (Propionibacterium avidum KP-40) and lectin blocking (D-galactose) prevents liver tumor colonization in BALB/c-mice | |
| RU2491101C1 (ru) | Способ профилактики раневых осложнений в абдоминопластике | |
| NZ197018A (en) | Propionibacterium preparation(injectable)tumour treatment | |
| IE51203B1 (en) | Cell-wall and whole-cell preparations for the treatment of tumours | |
| CN120310737A (zh) | 一种增强型脐带血nk细胞及其在防治神经母细胞瘤中的应用 | |
| DK157171B (da) | Anvendelse af propionibakterier til fremstilling af cellevaegpraeparater eller helcellepraeparater | |
| SK277936B6 (en) | Method of production of preparations from cell walls or whole cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Transfer of assignment of patent |
Owner name: PULVERER, GERHARD |
|
| MM | Patent lapsed | ||
| MM | Patent lapsed |
Owner name: PULVERER, GERHARD |